<DOC>
	<DOCNO>NCT00254540</DOCNO>
	<brief_summary>To determine objective tumor response single-agent SU011248 dose 50 mg orally daily 4 consecutive week 2 week rest , repeat every 6 week patient metastatic Renal Cell Cancer ( RCC ) .</brief_summary>
	<brief_title>Study SU011248 Patients With Advanced Kidney Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Histologically proven renal cell carcinoma metastases component clear cell histology Any cellular therapy ( LAK , TIL , DC ) , vaccine therapy , minitransplantation , systemic moleculartargeting therapy RCC .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>Ph2 , RCC , SU011248 , SUNITINIB</keyword>
</DOC>